Idorsia Ltd Idorsia Ltd

Idorsia Ltd

IDIA

Rank in Stocks #7690
Idorsia Ltd, a biopharmaceutical company, engages in the discovery,... Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Share Price
$4.74
Last synced: 2026-11-12
Market Cap
$1.26B
Change (1 day)
-2.37%
Change (1 year)
19.13%
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Category

Healthcare
Dividend history for Idorsia Ltd (IDIA)
Idorsia Ltd (stock symbol: IDIA) made a total of 1 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $12.17
Dividend yield (TTM) : 0.00%
Dividend payments for Idorsia Ltd (IDIA) from 2017 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
2026 (TTM) $12.17 0.00%
2017 $12.17 0.00%
List of all dividend payments
Year Dividend Change
2026 (TTM) $12.34 0.00%
2017 $12.34 0.00%
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
0.00%
US
0.00%
US
0.00%
US
69.00%
AU
30.00%
BE